Drug Type Bispecific antibody |
Synonyms- |
Target |
Action agonists, antagonists |
Mechanism CD28 agonists(T-cell-specific surface glycoprotein CD28 agonists), FAP antagonists(Fibroblast activation protein alpha antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Solid tumor | Preclinical | Germany | 05 Nov 2025 | |
| Solid tumor | Preclinical | Germany | 05 Nov 2025 | |
| Solid tumor | Preclinical | Germany | 05 Nov 2025 | |
| Solid tumor | Preclinical | Germany | 05 Nov 2025 |






